<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481597</url>
  </required_header>
  <id_info>
    <org_study_id>FDZJ1109DT</org_study_id>
    <nct_id>NCT01481597</nct_id>
  </id_info>
  <brief_title>Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers</brief_title>
  <official_title>Tolerance and Pharmacokinetics of Single-dose Intravenous Deuteporfin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deuteporfin, a novel photodynamic drug developed in China, displays good photodynamic&#xD;
      antitumor activity. The purpose of the present study is to investigate the safety and&#xD;
      pharmacokinetics of intravenous deuteporfin in healthy Chinese volunteers following&#xD;
      single-dose administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>up to 19 days following injection</time_frame>
    <description>number of participants with adverse events as a measure of safety and tolerability of single dose of deuteporfin administered to healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>predose, 20, 40 and 60 min during-dose, and 5, 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8 ,12, 24h post-dose</time_frame>
    <description>Pharmacokinetic profile: Cmax (Peak Concentration), AUC (area under the plasma-concentration-time curve ), T1/2 (half life)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>deuteporfin 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>deuteporfin 2.5mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>deuteporfin 5mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>deuteporfin 7.5mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deuteporfin</intervention_name>
    <description>deuteporfin 1 mg/kg IV as a single dose</description>
    <arm_group_label>deuteporfin 1mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deuteporfin</intervention_name>
    <description>deuteporfin 2.5 mg/kg IV as a single dose</description>
    <arm_group_label>deuteporfin 2.5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deuteporfin</intervention_name>
    <description>deuteporfin 5 mg/kg IV as a single dose</description>
    <arm_group_label>deuteporfin 5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deuteporfin</intervention_name>
    <description>deuteporfin 7.5 mg/kg IV as a single dose</description>
    <arm_group_label>deuteporfin 7.5mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese healthy male and/or female subjects&#xD;
&#xD;
          -  18 to 45 years old with Body mass index (BMI) within the range of 19 to 24 kg/m2&#xD;
&#xD;
          -  weigh at least 45 kg for female subjects or 50 kg for male subjects&#xD;
&#xD;
          -  In good health as confirmed by past medical history, physical examination,&#xD;
             electrocardiogram, laboratory tests and urinalysis on the screening and baseline&#xD;
             evaluation&#xD;
&#xD;
          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant illness or major surgery within four weeks prior to dosing&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies and photoallergy)&#xD;
&#xD;
          -  Use of any drugs which might interfere with drug absorption, distribution, metabolism,&#xD;
             excretion or cause photoallergy within 30 days prior to dosing, or any drugs within 14&#xD;
             days prior to dosing&#xD;
&#xD;
          -  Participation in any clinical investigation within 30 days prior to dosing&#xD;
&#xD;
          -  Smokers, alcoholics, drug abusers&#xD;
&#xD;
          -  Immunodeficiency diseases, including a positive HIV test result, Positive Hepatitis B&#xD;
             surface antigen (HBsAg) or Hepatitis C test result&#xD;
&#xD;
          -  pregnancy or lactation for female subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeneng Cheng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jining Tao, Master</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pingsheng Xu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital of Central-South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deuteporfin</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

